We are live on ! Find out more
TRAW icon

Traws Pharma
TRAW

12 hedge funds and large institutions have $8.23M invested in Traws Pharma in 2014 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

8% less funds holding

Funds holding: 13 → 12 (-1)

26% less capital invested

Capital invested by funds: $11.1M → $8.23M (-$2.83M)

33% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 3

91% less call options, than puts

Call options by funds: $4K | Put options by funds: $43K

Holders
12
Holders Change
-1
Holders Change %
-7.69%
% of All Funds
0.35%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
2
Closed
3
Calls
$4K
Puts
$43K
Net Calls
-$39K
Net Calls Change
+$17K

Top Buyers

Rank Fund Capital Flow
1
GPP
Great Point Partners
Connecticut
+$1.14M
2
Citigroup
Citigroup
New York
+$285K
3
HighTower Advisors
HighTower Advisors
Illinois
+$285K
4
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$285K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$569K
2
TC
TFS Capital
Pennsylvania
-$324K
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$285K
4
Goldman Sachs
Goldman Sachs
New York
-$285K
5
Northern Trust
Northern Trust
Illinois
-$285K
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
1
Sarissa Capital Management
Connecticut
$1.5M – – –
GPP
2
Great Point Partners
Connecticut
$1.49M +$1.14M +4 +200%
BFA
3
BlackRock Fund Advisors
California
$1.25M – – –
Vanguard Group
4
Vanguard Group
Pennsylvania
$1.07M – – –
Fidelity Investments
5
Fidelity Investments
Massachusetts
$615K -$285K -1 -25%
Citigroup
6
Citigroup
New York
$450K +$285K +1 +100%
WMSA
7
Weiss Multi-Strategy Advisers
New York
$430K – – –
Renaissance Technologies
8
Renaissance Technologies
New York
$246K -$569K -2 -67%
Royal Bank of Canada
9
Royal Bank of Canada
Ontario, Canada
$140K +$285K +1 New
HighTower Advisors
10
HighTower Advisors
Illinois
$125K +$285K +1 New
ARTA
11
A.R.T. Advisors
New York
$124K – – –
Geode Capital Management
12
Geode Capital Management
Massachusetts
$122K – – –
Goldman Sachs
13
Goldman Sachs
New York
$104K -$285K -1 Closed
Janney Montgomery Scott
14
Janney Montgomery Scott
Pennsylvania
$77.5K – – –
HK
15
Horizon Kinetics
New York
$77K – – –
Northern Trust
16
Northern Trust
Illinois
$55K -$285K -1 Closed
BCM
17
Bridgeway Capital Management
Texas
$52K – – –
ProShare Advisors
18
ProShare Advisors
Maryland
$48K – – –
VKH
19
Virtu KCG Holdings
New York
$48K – – –
TRCT
20
Tower Research Capital (TRC)
New York
$45K – – –
Millennium Management
21
Millennium Management
New York
$44K – – –
Group One Trading
22
Group One Trading
Illinois
$37K – – –
Wells Fargo
23
Wells Fargo
California
$30K – – –
Deutsche Bank
24
Deutsche Bank
Germany
$16K – – –
BIM
25
BlackRock Investment Management
Delaware
$9K – – –
1
2

TRAW Hedge Fund Activity: Q3 2014 in Review

12 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Traws Pharma (TRAW) for Q3 2014, worth a combined $8.23M — down 26% from $11.1M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of TRAW and 2 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 2 added.

The largest buyer was Great Point Partners, adding an estimated $1.14M. The largest seller was Renaissance Technologies, cutting an estimated $569K.

  • 12 institutional investors held Traws Pharma (TRAW) as of Q3 2014, down from 13 in Q2 2014.
  • Funds reported $8.23M of Traws Pharma stock for Q3 2014, down 26% quarter-over-quarter.
  • 2 funds opened new Traws Pharma positions in Q3 2014 and 3 closed out, a net change of -1 holder.
  • The largest Traws Pharma buyer in Q3 2014 was Great Point Partners, an estimated $1.14M added.
  • The largest Traws Pharma seller in Q3 2014 was Renaissance Technologies, an estimated $569K sold.

Based on aggregated 13F filings for Q3 2014.